Understand your drug better and increase success rates in early clinical development

Immuneed helps innovative biotechs advance their preclinical projects by providing a better understanding of their drug candidates. We are experts in immunology and pharmaceutical development and have experience working with a broad range of biotherapeutics. Immuneed offers services ranging from selecting the right drug candidate to evaluating infusion risks. Our expertise paired with our unique model of fresh, circulating human blood enables us to capture a breadth of the immune response not possible elsewhere. Immuneed's loop model is applicable during drug discovery and development – from screening of drug candidates to early clinical development. All our solutions are flexible and we tailor study design and project to address your specific needs

 

 

Contact Us!

Are you interested in our services to assess toxicity and/or efficacy of your drug candidate?

Get in touch to find out how we can help you!

I'm interested in






In order for us to get in touch with you we must store some of your data on our servers. Checking the 'I consent' box indicates that you have read our privacy policy which outlines how we process, protect and manage your data, and that you consent to us storing it in accordance with this policy.

I consent

NEWS

Immuneed will be attending Festival of Biologics in Basel 15-17 October - Immuneed will be attending the European Antibody Congress,  one of the most important gatherings of senior health and biologic professionals. This congress is a part of the Festival of Biologics is a prime opportunity to network with the event’s 1,500+ attendees, hear from more than 350 speakers, and explore what’s new in the Biologics industry. …
Cell lysis Are you forgetting something in preclinical trials? - Complement activation is a risk – even if the classical pathway is blocked. Preclinical testing is vital to ensure the safety of clinical trials. So why is a key aspect of the body’s immune system almost systematically overlooked in preclinical assays? The complement system comprises upwards of 40 blood proteins synthesized by the liver. When …
Immuneed and HepaPredict signs collaboration agreement. - Uppsala 2019-10-02 Swedish biotech companies Immuneed AB and HepaPredict AB have entered into a collaboration agreement, the signing of which was announced today. The agreement combines our two companies’ scientific expertise, specialized laboratory platforms and unique methodological know-how, enabling us to offer even better custimized solutions for our customers. HepaPredict’s expertise in hepatotoxicity predictions and …